Basel, January 12, 2014- Novartis announced today, that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect having decided to pursue a career opportunity outside of the organization.
星期日, 2014, 1月 12 - 13:00
Basel, January 12, 2014- Novartis announced today, that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect having decided to pursue a career opportunity outside of the organization. Alessandro Riva, M.D., Global Head, Novartis Oncology Development and Medical Affairs, will take on the role of President of Novartis Oncology ad interim, in addition to his current role, until a successor is named in due course.
Hervé has led the Oncology business since 2010 and we thank him for his dedication and commitment to bringing breakthrough treatments to patients. We wish him all the best for his future success.
About Novartis Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.